Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL)

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $37.00 price target on Castle Biosciences (NASDAQ: CSTL).

The analyst commented: 'We reiterate our BUY rating on Castle Biosciences (CSTL) shares and maintain our price target at $37. After the market close on Monday, November 3, the company reported 3Q25 results that were well ahead of our expectations and FactSet consensus. Castle's performance was partially driven by solid sequential test volume growth for TissueCypher (the market for which appears largely underpenetrated). Importantly, the company expects DecisionDx-SCC (DDx-SCC) to return to "material" consistent revenue in potentially the 2027/2028 time frame. Castle Biosciences also announced the launch of AdvanceAD-Tx to guide treatment decision-making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD). Importantly, the company raised its 2025 revenue guidance. In our opinion, Castle could drive solid long-term revenue growth by further penetrating its maturing dermatologic cancer market opportunity, maintaining strong TissueCypher momentum and executing on reimbursement for its new AdvanceAD-Tx test and robust test pipeline. We view the company's shares as highly attractive at current levels."

For an analyst ratings summary and ratings history on Castle Biosciences click here. For more ratings news on Castle Biosciences click here.

Shares of Castle Biosciences closed at $25.99 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters